BACKGROUND
Lung cancer is the most common type of
cancer throughout the world, and the morbidity of
lung cancer is continuously increasing. Patients with advanced
lung cancer often cannot tolerate
chemoradiotherapy. The decrease of the expression of miRNA-21 can be used as an
indicator of the
therapeutic effect of
lung cancer. In this study, the effect of
Kanglaite injection on serum miRNA-21 in patients with advanced
lung cancer was investigated, providing reliable and important evidences. MATERIAL AND METHODS From March 2016 to March 2017, 120 patients with advanced
lung cancer were examined; we collected detailed information and serum samples. The patients were treated by
intravenous drip of
Kanglaite, which was provided by Zhejiang
Kanglaite Pharmaceutical Co., Ltd., China. We administered 200 ml
intravenous drip once per day for a total of 21 days. Serum samples were collected from patients
after treatments. In this study, 4 observation indexes were considered - KPS (Karnofsky performance score, KPS),
body weight, adverse effects, and miRNA-21 level - evaluated before and after the
Kanglaite treatment. RESULTS Among 120 patients with advanced
lung cancer, the KPS of 75 patients (63.1%) was increased after the treatment, and
body weight was increased by 55.9%. In addition, serum miRNA-21 level after the
Kanglaite treatment was 2.45±0.15, which was significantly lower than before treatment (3.87±0.54), (P<0.05). CONCLUSIONS The effect of
Kanglaite injection on serum miRNA-21 in patients with advanced
lung cancer was shown to significantly reduce the expression of miRNA-21, providing objective evidence for the effect of
Kanglaite injection in patients with advanced
lung cancer.